Octant

Octant engineers biology and chemistry at massive scales to modulate cellular function itself, targeting complex cellular mechanisms that drive disease with a focus on correcting protein misfolding and mistrafficking.

OCT-980, their first-in-disease oral small molecule for rhodopsin-associated autosomal dominant retinitis pigmentosa, has shown strong efficacy and favorable safety profile in preclinical studies, with Phase 1a clinical trials initiated in Q1 2026.